Copyright
©The Author(s) 2025.
World J Clin Oncol. May 24, 2025; 16(5): 103830
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.103830
Published online May 24, 2025. doi: 10.5306/wjco.v16.i5.103830
Figure 1 Immunohistochemical results of homeobox C6.
A: Protein expression of homeobox C6 (HOXC6) in para-cancer tissues of bladder cancer (BLCA); B: Protein expression of HOXC6 in BLCA.
Figure 2 Comprehensive evaluation of the mRNA expression and discernibility ability of homeobox C6 in bladder cancer based on global microarray data.
A: Forest plot of the homeobox C6 (HOXC6) standardized mean difference in bladder cancer; B: Publication bias by funnel plots of Egger’s test; C: The summary receiver operating characteristic curve of HOXC6. AUC: Area under the curve; SROC: Summary receiver operating characteristic curve; SMD: Standardized mean difference; BLCA: Bladder cancer.
Figure 3 Relative mRNA expression of homeobox C6 in bladder cancer cell lines.
A: Relative mRNA expression of homeobox C6 (HOXC6) in EJ-1, 5637, J82, and HT-1376 (compared to the EJ-1 group); B: Relative expression of HOXC6 after transfection with siRNA (compared to 5637 + control group). cP < 0.005; dP < 0.001; CK: Control group; NC: Negative control group; HOXC6: Homeobox C6.
Figure 4 Effect of down-regulated homeobox C6 on cell biological function.
A: The CCK-8 test for cell proliferation; B: Cell wound healing assay; C: Transwell experiment; D: Apoptosis assay; E: Cell cycle detection. The 5637 was the blank group. The 5637 + negative control group was the control siRNA group. The 5637 + si-homeobox C6 (HOXC6) group was the transfected with si-HOXC6. Compared to 5637 group. cP < 0.005; dP < 0.001; NC: Negative control group; HOXC6: Homeobox C6.
Figure 5 The result of pathway enrichment analysis with homeobox C6 target genes.
BP: Biological process; CC: Cellular component; MF: Molecular function; KEGG: Kyoto Encyclopedia of Genes and Genomes.
Figure 6 The identification of homeobox C6 target genes.
A: Venn diagram. I represents the target genes of homeobox C6 (HOXC6) from CistromDB, II represents genes positively correlated with HOXC6 expression in bladder cancer (BLCA), and III represents upregulated genes in BLCA; B: MRNA expression correlation analysis between HOXC6 and TIMELESS; C and D: MRNA expressions of HOXC6 and TIMELESS in BLCA; E: Binding peak of HOXC6 binding to the promoter region of TIMELESS, with data from CistromDB. aP < 0.05; BLCA: Bladder cancer; HOXC6: Homeobox C6.
- Citation: Lu DJ, Wang HR, Xu YS, Huang HB, Zhong QG, Luo YN, Qi JF, Wu HC, Pei JY, Zhang K, Xu CX, Wang TX, Zhang W, Zhou YH, Huang ZG, Wang FB. Homeobox C6 plays an oncogenic role in bladder cancer. World J Clin Oncol 2025; 16(5): 103830
- URL: https://www.wjgnet.com/2218-4333/full/v16/i5/103830.htm
- DOI: https://dx.doi.org/10.5306/wjco.v16.i5.103830